Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

Open-label Phase 1b single-group study administering psilocybin in three ascending oral doses to patients with chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA).

Primary aims are safety and tolerability; secondary aims include effects on cognition and exploratory change in attack frequency, duration, and intensity.